David A. Siegel Ovid Therapeutics Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 151,800 shares of OVID stock, worth $198,858. This represents 0.0% of its overall portfolio holdings.

Number of Shares

151,800

Holding current value

$198,858

% of portfolio

0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$0.32 - $1.73 $48,576 - $262,614	151,800 New	151,800 $194,000
Q4 2022 Feb 14, 2023	SELL	$1.43 - $1.89 $6,149 - $8,127	-4,300 Reduced 23.5%	14,000 $26,000
Q3 2022 Nov 14, 2022	SELL	$1.84 - $2.26 $10,120 - $12,429	-5,500 Reduced 23.11%	18,300 $34,000
Q2 2022 Aug 15, 2022	SELL	$1.69 - $3.31 $17,914 - $35,086	-10,600 Reduced 30.81%	23,800 $51,000
Q1 2022 May 16, 2022	SELL	$2.65 - $3.49 $33,655 - $44,323	-12,700 Reduced 26.96%	34,400 $108,000

Q4 2021 Feb 14, 2022	SELL	$3.13 - $3.73 $190,617 - $227,157	-60,900 Reduced 56.39%	47,100 $151,000
Q3 2021 Nov 15, 2021	SELL	$3.31 - $4.04 $742,102 - $905,768	-224,200 Reduced 67.49%	108,000 $363,000
Q2 2021 Aug 16, 2021	BUY	$3.3 - $4.49 $41,580 - $56,574	12,600 Added 3.94%	332,200 $1.3 Million
Q1 2021 May 17, 2021	SELL	$2.42 - $4.47 $662,596 - $1.22 Million	-273,800 Reduced 46.14%	319,600 $1.29 Million
Q4 2020 Feb 16, 2021	BUY	$2.28 - $6.84 $969,455 - $2.91 Million	425,200 Added 252.79%	593,400 $1.37 Million
Q3 2020 Nov 16, 2020	BUY	$5.39 - $8.24 $906,598 - $1.39 Million	168,200 New	168,200 $965,000
Q2 2020 Aug 14, 2020	SELL	$2.67 - $7.91 $62,478 - $185,094	-23,400 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.03 - $4.35 $8,526 - $18,270	4,200 Added 21.88%	23,400 $70,000
Q4 2019 Feb 14, 2020	BUY	$2.08 - $5.06 $39,936 - $97,151	19,200 New	19,200 $80,000

Others Institutions Holding OVID

# of Institutions

Shares Held

33.1M

Call Options Held

141K

Put Options Held

62.5K

View Full List

About Ovid Therapeutics Inc.

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $92.2M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

More about OVID

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account